Avalon Globocare Corp Stock Price, News & Analysis

Avalon GloboCare (NASDAQ: ALBT) has launched the 'BrAce for Impact' affiliate marketing program for KetoAir™, an AI-enabled breathalyzer device for ketogenic health monitoring. The program, developed following demand from recent health conferences, offers affiliates discount codes and commissions on sales.

The initiative provides marketing materials and brand resources to affiliates, targeting metabolic coaches, podcasters, health authors, and influencers. KetoAir™, FDA-registered (No. 3026284320), measures breath acetone concentration using nano-sensor technology to assess ketosis status, with companion apps available on both Apple and Google platforms.

Avalon GloboCare (NASDAQ: ALBT) has appointed Dr. Charles Cavo to its Scientific and Clinical Advisory Board to support the development of KetoAir™, a handheld breathalyzer for ketogenic health monitoring. Dr. Cavo, co-founder and CMO of Pounds Transformation, brings expertise in obesity medicine and bariatric care. KetoAir™ measures Breath Acetone Concentration (BrAce) as a biomarker for ketosis, offering a non-invasive alternative to blood and urine testing. The device aims to support weight management and conditions like diabetes by providing real-time feedback on ketosis levels.

Avalon GloboCare (NASDAQ: ALBT) has entered into a memorandum of understanding with Qi Diagnostics to explore co-developing a VOC nanosensor-based cannabis breathalyzer. The MOU grants Avalon a 120-day exclusivity period to negotiate a definitive agreement. If successful, the collaboration would focus on developing a prototype for detecting cannabis, leveraging Avalon's regulatory expertise and experience with clinical trials. The project aims to address point-of-care testing needs in law enforcement and workplace safety. However, there is no guarantee that a definitive agreement will be reached during the exclusivity period.

Avalon GloboCare (NASDAQ: ALBT) has announced a 1-for-15 reverse stock split effective October 28, 2024, as part of its strategy to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The reverse split will reduce outstanding common shares from approximately 16.0 million to 1.1 million. The company will continue trading under the symbol 'ALBT' with a new CUSIP number 05344R302. The move is aimed at maintaining Nasdaq listing while the company continues focusing on its precision diagnostics and laboratory services business.

Avalon GloboCare Corp. (NASDAQ: ALBT) has announced its sponsorship of the Keto Pa-LOU-za 2024 Conference, taking place October 11-13, 2024, in Louisville, KY. The company will showcase its KetoAir™ breathalyzer device, designed to monitor ketosis through breath analysis. Conference attendees will have the opportunity to see live demonstrations and purchase the device along with related accessories on-site.

The KetoAir™ breathalyzer is a handheld device specifically engineered for ketogenic health management. It measures breath acetone concentration (BrAce) to assess ketosis status without invasive blood tests. The device is FDA-registered and accessible via both Apple App Store and Google Play Store. Avalon's subsidiary, Q&A Distribution , holds exclusive distributorship rights for KetoAir™ in North America, South America, EU, and UK.

Avalon GloboCare Corp. (NASDAQ: ALBT) announced that Laboratory Services MSO, (LSM), in which Avalon owns a 40% stake, will begin manufacturing and selling the GeeWhiz External Condom Catheter, an FDA-registered male incontinence device. The product launch is planned for Q3 2024. The device is approved for Medicare reimbursement and supported by several private insurers.

The global male urinary incontinence market, valued at $6.37 billion in 2022, is projected to grow at a CAGR of 5.87% from 2023 to 2030. This growth is driven by increasing incontinence prevalence, an aging population, and technological advancements. The GeeWhiz catheter aims to provide enhanced comfort, security, and ease of use for men with urinary incontinence and bladder control issues.

Avalon GloboCare Corp. (NASDAQ: ALBT) has announced the launch of a direct-to-consumer DNA test for opioid addiction predisposition through its 40% owned Laboratory Services MSO. The DNA4Addiction test analyzes 15 genetic markers linked to opioid dependence, categorizing individuals into risk levels. This non-invasive, at-home test comes amid the ongoing opioid crisis, with opioids involved in over 75% of nearly 107,000 drug overdose deaths in 2022.

The test aims to provide insights for proactive health management, though it is not a diagnosis. It examines factors such as neurotransmitter activity and substance sensitivity. Dr. David Jin, CEO of Avalon, emphasized the importance of recognizing genetic predisposition for early intervention. Bob Forrest, Brand Ambassador for DNA4Addiction, highlighted its potential in guiding lifestyle changes and preventing addiction, especially for parents concerned about their children's risks.

Avalon GloboCare Corp. (NASDAQ: ALBT) has launched online sales of the KetoAir™ breathalyzer in the U.S. at www.ketoair.us. This FDA-registered device features Hot App shareable technology with AI-enabled software for ketogenic health management. The KetoAir™ breathalyzer uses nano-sensor-based technology and AI algorithms to assess ketosis status and record diet and exercise details via its app.

The device offers personalized nutritional and exercise recommendations through its AI nutritionist feature. Avalon has exclusive distributorship rights for KetoAir™ in North America, South America, EU, and the UK. To celebrate the launch, Avalon is offering a special introductory price of $199 (regular $249) with an additional 20% discount using coupon code 'intro20'.

Avalon GloboCare announced the successful U.S. launch of its KetoAir™ breathalyzer at the Hack Your Health by KetoCon 2024 Conference. The event, held from May 31 to June 2, 2024, in Austin, Texas, attracted diverse stakeholders such as doctors, health coaches, and retailers. The device, registered with the FDA (No. 3026284320), uses AI-enabled software and nano-sensor technology to monitor ketosis through a non-invasive breath test. Avalon introduced a Zero to Keto program and expects retail sales to begin later this month, with purchases available exclusively at KetoAir.com.